ClinicalTrials.gg
CompletedNCT04126681Updated Mar 3, 2025

A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase

A Phase 2 interventional study of HQP1351 and Hydroxyurea or Interferon-based therapy in Chronic Myeloid Leukemia, Chronic Phase, sponsored by Ascentage Pharma Group Inc.. Completed at 22 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-03.

Primary conditionLeukemia, Myelogenous, Chronic, BCR-ABL PositiveRegistry: Leukemia, Myeloid, Chronic-PhaseReclassifiedWhy we changed it
Registry
Leukemia, Myeloid, Chronic-Phase — the first condition term the registry derived for this study.
ClinicalTrials.gg
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Why
  1. Leukemia, Myeloid, Chronic-Phase is a broad heading, used only when no more specific condition is named.
  2. The study's listed conditions name Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Ascentage Pharma Group Inc. (part of Ascentage Pharma Group International) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
144
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 49 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in China — 11 open to participants now, 14 under way, 2 of them phase 3. Leukemia, Myelogenous, Chronic, BCR-ABL Positive · China.

Enrollment
19th of 37
144 · median 144
Started
2019
with 2 others
Phase 2
10 of 49
2 open now
Registered
24th of 49
by date
Lead sponsor
2 of 49
Ascentage Pharma Group Inc.

Among the 49 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in China, this one is the 19th largest by enrollment of the 37 interventional ones that give a count, is one of 3 that started in 2019, is one of 10 in phase 2, and was the 24th registered.

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

894 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 109 are open to participants now.

Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →

Open to participants now

11 of the 49 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in China are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 79 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies recruiting now, 48 (61%) set no upper age limit and 20 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy of HQP1351 in patients with chronic myeloid leukemia in chronic phase (CML-CP) who are resistant and/or intolerant to first- and second-generation tyrosine kinase inhibitors. The efficacy of HQP1351 is determined by evaluating the subjects' event free survival (EFS).

Read the detailed description

This is a phase 2, randomized, open label, pivotal study to evaluate the efficacy and safety of HQP1351 in CML CP patients who are resistant and/or intolerant to first- and second-generation TKIs in China. A total of 141 CML CP patients will be included in this study. After screening, eligible subjects will be randomized by 2:1 ratio to enter HQP1351 therapy cohort and best available therapy (BAT) cohort. When the subjects in the two cohorts reach EFS assessment, they can crossover to contralateral cohort if the investigator and Sponsor think they could be clinically benefited. During treatment, each subject will be assessed regularly for hematological, cytogenetic and molecular responses. At the same time, safety information also will be evaluated.

03

Conditions studied

  • Chronic Myeloid Leukemia, Chronic Phase

Browse trials for

Keywords

  • Chronic Myeloid Leukemia
  • HQP1351
  • CML
  • CML-CP
  • Olverembatinib Tablets
04

In context

Leukemia, Myelogenous, Chronic, BCR-ABL Positive Reclassified

894 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 109 are open to participants now.

This study's enrollment of 144 is above the median of 44 across 681 interventional studies indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive.

Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →

Lead sponsor

Ascentage Pharma Group Inc. is the lead sponsor of 53 studies on the registry; 31 are open to participants now.

Compared within Leukemia, Myelogenous, Chronic, BCR-ABL Positive, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Leukemia, Myeloid, Chronic-Phase. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or non-pregnant, non-lactating female patients who are 18 years of age or older.
  2. CML-CP patients with positive Ph chromosome or BCR-ABL fusion genes.
  3. Resistance and intolerance of first- and second-generation TKIs: defined as resistance or intolerance to imatinib, nilotinib, and dasatinib.
  4. Ability to understand and willingness to sign a written form. The consent form must be signed by the patient prior to any study specific procedures.
  5. (ECOG) Performance Status ≤ 2.
  6. Predicted of ≥3 months.
  7. Organ function as indicated by the following laboratory indicators must be met (Hematological indicators require that no blood transfusion or any blood products or cytokines be used within 14 days prior to testing):

    • ≥8.0g/dL.
    • White blood cell count ≥ 3.0×10\^9/L.
    • count ≥ 75×10\^9/L.
    • Serum creatinine ≤ 1.5× (ULN) or 24 hours calculated ≥ 50mL/min when serum creatinine >1.5×ULN.
    • Serum albumin ≥ 3.0 g/dL.
    • Total ≤ 1.5 x ULN.
    • (AST) and Alanine aminotransferase (ALT) ≤ 2.5 x ULN.
    • Amylase≤1.5×ULN. Lipase≤1.5×ULN.
    • PT//INR≤1.5×ULN.
  8. Cardiac function index: (EF) > 50%, pulmonary arterial systolic pressure (PASP) ≤50 mmHg.
  9. corrected on (ECG) evaluation: QTc≤450ms in males or ≤470ms in females.
  10. Males and females of and their partners voluntarily take measures that the researchers believe are effective within 120 days from the signing of the informed consent to the last use of the research drug, or confirm that sterilization has been performed (at least one month before screening).
  11. Willingness and ability to comply with study procedures and follow-up examination.

Exclusion criteria

Exclusion Criteria:

  1. Received cytotoxic chemotherapy or radiotherapy within 28 days prior to the first administration, interferon or cytarabine or antitumor effect Chinese herbal medicine or Chinese patent medicine within 14 days prior to the first administration, or targeted BCR-ABL1 TKI within 7 days prior to the first administration, or hydroxyurea or anagrelide within 24 hours after the first administration, or adverse events (except alopecia) caused by previous treatment and have not recovered.
  2. The patients who received any other investigating drugs within 14 days prior to first administration.
  3. For patients with CML-CP, if they have progressed to AP or BP, they cannot be enrolled after treatment with CML-CP.
  4. Patients who are currently receiving treatment with a medication that has the potential to interact with research drug.
  5. Have previously been treated with ponatinib or HQP1351 (or drugs of similar composition).
  6. Absorption disorder syndrome or other diseases affecting oral drug absorption.
  7. Have any history of heart or vascular disease, such as hypertension (systolic blood pressure (HBP) > 140mmHg and/or diastolic blood pressure > 90mmHg), or take medications that are known to cause prolongation. The patients with well controlled HBP can be included.
  8. Pulmonary systolic pressure (PSP) of echocardiography is more than 50 mmHg, or there is clinical symptom related to pulmonary hypertension.
  9. Have a history of serious cardiovascular diseases during the previous treatment of chronic myeloid leukemia with TKI, including myocardial infarction, unstable angina pectoris, severe arrhythmia and congestive heart failure.
  10. Underwent or allogeneic stem cell transplant.
  11. CML-CP patient currently diagnosed as Complete cytogenetic response (CCyR).
  12. Have diseases with abnormal bleeding and coagulation function, or have a bleeding disorder unrelated to CML within 3 months before first dose of study drug.
  13. Underwent major surgery (except minor surgical procedures, such as placement or bone marrow ) with 14 days prior to the first dose of study drug.
  14. Require concurrent treatment with agents, other than prescribed for a short course of therapy (It is defined as a daily dose of corticosteroids less than 30 mg prednisone or the same amount of other corticosteroids within 7 days).
  15. Have active nervous system (CNS) disease as evidence by cytology or pathology. In the absence of clinical CNS disease, lumbar puncture is not required.
  16. History of another primary .
  17. Active symptomatic infection.
  18. Known to be allergic to study drug ingredients or their analogues.
  19. Female patients with blood β-Human chorionic gonadotropin positive, pregnant or lactating or expecting pregnancy during the study program.
  20. Suffer from any condition or illness that, in the opinion of the Investigator or the medical monitor, would compromise patient safety or interfere with the evaluation of the safety of the research drug.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
144 participants (actual)

Study arms

  • Experimental
    HQP1351 therapy cohort

    HQP1351 40 mg, taken orally once every other day of a 28-day cycle

    Drug: HQP1351

  • Active comparator
    Best Available Therapy (BAT) cohort

    Best available therapy (BAT) will be selected by the investigator for each participant.

    Drug: Hydroxyurea or Interferon-based therapy · Drug: Homoharringtonine · Drug: Imatinib, Dasatinib or Nilotinib

Interventions

  • HQP1351 is a new, bioavailable inhibitor against BCRABLWT and a broad spectrum of BCR-ABL mutants including BCR-ABLT315I

  • DrugHydroxyurea or Interferon-based therapy

    Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines.

  • Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines.

  • DrugImatinib, Dasatinib or Nilotinib

    Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines.

07

What researchers measure

Primary outcomes

  1. Event free survival (EFS)

    EFS is defined as any "event" occurred since randomization, such as disease progression.

    Time frame: By the end of Cycle 24 (each cycle is 28 days)

Secondary outcomes

  1. Complete hematologic response (CHR)

    CHR is the proportion of patients achieving CHR after being treated. It is defined as the best response obtained by the subjects during the whole treatment process of the study.

    Time frame: By the end of Cycle 24 (each cycle is 28 days)

  2. Major cytogenetic response (MCyR)

    MCyR is the proportion of patients achieving Complete cytogenetic response (CCyR: defined as 0% Philadelphia chromosome-positive \[Ph+\] metaphases by cytogenetic analysis of bone marrow) or Partial Cytogenetic Response (PCyR: defined as \>0% to 35% Ph+ metaphases by cytogenetic analysis of bone marrow). It is defined as the best response obtained by the subjects during the whole treatment process of the study.

    Time frame: By the end of Cycle 24 (each cycle is 28 days)

  3. Complete cytogenetic response (CCyR)

    CCyR is the proportion of patients achieving CCyR after being treated. It is defined as the best response obtained by the subjects during the whole treatment process of the study.

    Time frame: By the end of Cycle 24 (each cycle is 28 days)

  4. Major molecular response (MMR)

    MMR is the proportion of patients achieving a ratio of ≤0.1% breakpoint cluster region (BCR) abelson leukemia (ABL) to ABL transcripts on the international scale (≤0.1% BCR-ABL/ABL\[IS\]) after being treated with HQP1351. It is defined as the best response obtained by the subjects during the whole treatment process of the study.

    Time frame: By the end of Cycle 24 (each cycle is 28 days)

  5. Progression free survival (PFS)

    PFS is defined as the interval between the first dose date and the first date at which the criteria for progression are met, or death. The subject who isn't progression or death will be censored at the last response assessment.

    Time frame: By the end of Cycle 24 (each cycle is 28 days)

  6. Overall survive (OS)

    OS is defined as the interval between the first dose date and date of death, censored at the last contact date to be alive.

    Time frame: By the end of Cycle 24 (each cycle is 28 days)

  7. Incidence and severity of adverse events

    Adverse events (AEs), and serious AEs (SAEs): Patients treatment related AE, SAE will be assessed according NCI CTCAE Version 5.0.

    Time frame: By the end of Cycle 24 (each cycle is 28 days)

08

Study locations

22 sites
  • Peking University People's Hospital
    Beijing, Beijing 100044, China
  • Sun Yat-sen University Cancer Center
    Guangzhou, Gongdong, China
  • Nanfang hospital of southern medical university
    Guangzhou, Guangdong 510515, China
  • Shenzhen Second People's Hospital
    Shenzhen, Guangdong, China
  • The First affiliated hospital of Guangxi Medical University
    Nanning, Guangxi, China
  • Henan Provincial Oncology Hospital
    Zhengzhou, Henan 450003, China
  • Henan Provincial people's Hospital
    Zhengzhou, Henan, China
  • Tongji Hospital medical college Huazhong University of Science and Technology
    Wuhan, Hubei 430022, China
  • Union Hospital medical college Huazhong University of Science and Technology
    Wuhan, Hubei 430022, China
  • Zhongnan Hospital of Wuhan University
    Wuhan, Hubei, China
  • Xiangya Hospital Central South University
    Changsha, Hunan, China
  • Jiangsu Province Hospital
    Nanjing, Jiangsu, China
  • The First Affiliated Hospital of Soochow University
    Suzhou, Jiangsu, China
  • The First affiliated hospital of Nanchang University
    Nanchang, Jiangxi, China
  • First Hospital of Jilin University
    Changchun, Jilin, China
  • The Affiliated hospital of Qingdao University
    Qingdao, Shandong, China
  • Qilu hospital of Shandong University
    Jinan, Shangdong, China
  • Ruijing Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
    Shanghai, Shanghai 200032, China
  • West China Hospital of Sichuan University
    Chengdu, Sichuan, China
  • Blood Diseases Hospital Chinese Academy of Medical Sciences
    Tianjin, Tianjin, China
  • The First Affiliated Hospital, Zhejiang University School of Medicine(hematology dept)
    Hangzhou, Zhejiang, China
  • The First Affiliated Hospital, Zhejiang University School of Medicine(HSCTdept)
    Hangzhou, Zhejiang, China
09

References and documents

Publications

  • Jiang Q, Li Z, Qin Y, Li W, Xu N, Liu B, Zhang Y, Meng L, Zhu H, Du X, Chen S, Liang Y, Hu Y, Liu X, Song Y, Men L, Chen Z, Niu Q, Wang H, Lu M, Yang D, Zhai Y, Huang X. Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial. J Hematol Oncol. 2022 Aug 18;15(1):113. doi: 10.1186/s13045-022-01334-z. PubMed 35982483 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2019 to primary completion in Aug 2024, 57 months.

Of 25 industry-sponsored phase 2 interventional studies under Leukemia, Myelogenous, Chronic, BCR-ABL Positive, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 69. This study's 57 months is above that.

Counting every sponsor, half of 126 studies reached it within 73 months; a quarter within 43 and three quarters within 124.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2019
First posted
Oct 15, 2019
StartActual
Oct 21, 2019
Primary completionActual
Aug 1, 2024
CompletionActual
Aug 1, 2024
Last update
Mar 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04126681
Collaborators
HealthQuest Pharma Inc.
Responsible party
Sponsor
First posted
Oct 15, 2019
Start date
Oct 21, 2019
Primary completion
Aug 1, 2024
Completion
Aug 1, 2024
Last update
Mar 3, 2025

Study contacts

Xiaojun Huang, Professor
principal investigator · Peking University People's Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olverembatinib

Start the discussion